NNC0487-0111

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ObesityType 2 DiabetesDiabetes Mellitus

190 competitors in Obesity

#DrugCompanyPhaseTrials

1

Synthroid

IInstitut Jerome Lejeune

Phase 3

12

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

13

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

44

NNC0487-0111

Novo Nordisk

Phase 3

115

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

16

Berobenatide

Pfizer

Phase 3

37

Mibavademab

Regeneron

Phase 3

28

Survodutide

Boehringer Ingelheim

Phase 3

29

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

210

Avapro

Sanofi

Preclinical

1Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity11 trials

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Completed·Novo Nordisk·Phase 1·NCT06049329·36 enrolled

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Japanese Participants With Overweight or Obesity (AMAZE 10)

Recruiting·Novo Nordisk·Phase 3·NCT07822061·400 enrolled

Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)

Active, not recruiting·Novo Nordisk·Phase 3·NCT07503210·606 enrolled

Show 8 more trials

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)

Recruiting·Novo Nordisk·Phase 3·NCT07571005·300 enrolled

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)

Recruiting·Novo Nordisk·Phase 3·NCT07571109·300 enrolled

The Effect of Once-weekly Subcutaneous NNC0487-0111 Compared to an Energy-restricted Diet or Placebo on Energy Metabolism in Adults Living With Obesity: a Randomised, Placebo-controlled Study

Recruiting·Novo Nordisk·Phase 1·NCT07757087·120 enrolled

Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Oral Doses of NNC0487-0111 in Chinese Participants With Overweight or Obesity

Completed·Novo Nordisk·Phase 1·NCT06820476·29 enrolled

Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Recruiting·Novo Nordisk·Phase 3·NCT07567001·5,610 enrolled

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)

Recruiting·Novo Nordisk·Phase 3·NCT07509307·400 enrolled

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)

Recruiting·Novo Nordisk·Phase 3·NCT07481630·400 enrolled

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)

Recruiting·Novo Nordisk·Phase 3·NCT07339423·1,150 enrolled

Overweight3 trials

A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity

Completed·Novo Nordisk·Phase 1·NCT06478563·133 enrolled

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

Completed·Novo Nordisk·Phase 1·NCT05369390·144 enrolled

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Completed·Novo Nordisk·Phase 2·NCT06064006·125 enrolled

Women1 trial

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant

Completed·Novo Nordisk·Phase 1·NCT06461039·43 enrolled

Function1 trial

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Completed·Novo Nordisk·Phase 1·NCT06559527·42 enrolled

Skin1 trial

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

Completed·Novo Nordisk·Phase 1·NCT07121153·36 enrolled

3 more indications

Type 2 Diabetes1 trial

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Not yet recruiting·Novo Nordisk·Phase 3·NCT07400107·1,000 enrolled

Diabetes Mellitus1 trial

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)

Recruiting·Novo Nordisk·Phase 3·NCT07533175·630 enrolled

Type 2 Diabetes Mellitus1 trial

Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study

Completed·Novo Nordisk·Phase 2·NCT06542874·448 enrolled

Details

Drug Info

Related News